Skip to main content
SpringerLink
Log in

Generic antiretrovirals − a controversial option?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Walensky RP, et al. Economic savings versus health losses: the costeffectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine 158: 84-92, No. 2, 15 Jan 2013. Available from: URL: http://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002.

    PubMed  Google Scholar 

  2. Sherer R. Generic Antiretrovirals and the Uncertain Future of HIV Care in the United States. Annals of Internal Medicine 158: 133-4, No. 2, 15 Jan 2013. Available from: URL: http://dx.doi.org/10.7326/0003-4819-158-2-201301150-00010.

    PubMed  Google Scholar 

Download references

Additional information

* the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-US model

** incremental cost-effectiveness ratio

Rights and permissions

Reprints and permissions

About this article

Cite this article

Generic antiretrovirals − a controversial option?. PharmacoEcon Outcomes News 670, 1 (2013). https://doi.org/10.1007/s40274-013-0075-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0075-5

Search

Navigation